Fig. 2From: SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemnessSHP2 reduce the sensitivity of T790M mutant LUAD cells to Osimertinib. AÂ Lentiviral transfected LUAD cells were generated to modify SHP2 expression, Lv-SHP2 plasmids were labeled in green with GFP reporter expression, Lv-SHP2RNAI plasmids in red with mCherry reporter expression, and SHP2 expression was confirmed by western blot (right panel). BÂ The viability of PC9 and PC9GR cells with over-expressed SHP2 were significantly higher than that of their parental cells in a dose dependent manner, while the viability of SHP2 knock-down cells were significantly lower than that of their parental cells. CÂ High SHP2-expressing PC9 and PC9GR cells formed substantially larger residual crystal violet than that of their parental cells when co-cultured with Osimertinib, while the residual crystal violet generated by SHP2 knock-down cells was obviously decreased. DÂ Osimertinib dramatically shrunk the tumor size of PC9GR tumor in vivo. E, Osimertinib significantly reduced the tumor size of SHP2 inhibited PC9GR cells than SHP2 over-expressing PC9GR cells. F, the proportion of Ki67 and CD133 positive CSCs was much higher in LV-SHP2 PC9GR tumor than in LV-SHP2RNAI tumor of Osimertinib administration. Each experiment was repeated 3 timesBack to article page